Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease [Yahoo! Finance]
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $18.00 price target on the stock.
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its price target lowered by analysts at Wedbush from $10.00 to $8.00. They now have a "neutral" rating on the stock.